Augmentative Transcranial Direct Current Stimulation (tDCS) in Patients With Bipolar Depression: RCT, IIT Study.
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- tDCS
- Sponsor
- Seoul National University Hospital
- Enrollment
- 64
- Locations
- 1
- Primary Endpoint
- Response rate of treatment
- Last Updated
- 6 years ago
Overview
Brief Summary
The purpose of this study is to determine whether transcranial direct current stimulation (tDCS) is effective and safe in the treatment Bipolar depression.
Randomized, double-blind Controlled Clinical Trial. Subjects Adults (between 19 and 65 years of age) with Bipolar depression who meet the inclusion criteria and who agree to participate in the study Will recruit from clinical referrals.
- Active tDCS Anode - left DLPFC Cathode - right DLPFC Electric current is 2mA - Current is applied for 30 min
- Sham tDCS Same assembly is used Current is applied for 1 min
Both groups 30~42 stimulation sessions on consecutive days.
Baseline(visit 1), 2 week(visit 2), 4 week(visit 3), 6 week(visit 4), and 12 week(visit 5) Check compliance with mobile application(MINDD-CONNECT) connections.
Detailed Description
Assessment: Depression rating scale: HAM-D(Hamiltion Depresiion Rating Scale), HAM-A(Hamilton Anxiety Rating Scale) Maniac rating scale: YMRS(Young Mania rating scale) CGI-BP(Clinical Global Impression-Bipolar) Q-LES-Q-SF(Quality of Life Enjoyment and Satisfaction Short form) Q-LES-Q-Q(Quality of Life Enjoyment and Satisfaction Questionnaire) qEEG(Quantitative Electroencephalography) Check compliance with mobile application(MINDD-CONNECT) connections.
Investigators
Woojae Myung
Principal Investigator
Seoul National University Hospital
Eligibility Criteria
Inclusion Criteria
- •Type I or Type II of bipolar disorder meets the current major depression diagnostic criteria in DSM-5
- •CGI Severity of lightness score ≥ 4 points
- •Taking mood stabilizers for at least four weeks before the day of screening
Exclusion Criteria
- •A history of clinically significant internal neurological disorders or head injury
- •mental retardation or cognitive impairment that will affect to make a consent form.
- •Patients at risk of suicide that may require hospitalization as determined by clinicians
- •A person who is determined to be excluded for using tDCS medical device for other reason (e.g. metal plate is inserted on head, etc.)
- •A person who is determined to have problems with scalp deformation, inflammatory response or brain wave and attachment of direct current because of other dermatological problem
- •A woman who disagree with medically allowed contraception\* until 24 weeks after the application of investigational device among woman subject who is possible to get pregnant
- •\* Medically allowed contraception: condom, oral contraception for at least 3 month, injection or insert contraception, Intrauterine Device, etc.
- •pregnant woman or lactating woman
- •A person who is not suitable for this clinical trial based on principal investigator's determination other than above reasons
Outcomes
Primary Outcomes
Response rate of treatment
Time Frame: baseline, 6week
Response group: Reduce of HAM-D 50%
The changes in HAM-D
Time Frame: baseline, 2week, 4week, 6week
The changes in HAM-D(Hamilton Depression scale) will constitute the major research outcome measure. HAM-D17 * clinician-administered scale * assesses 17 items related to major depression (MD) * Individual items scored on 3 point (0 to 2) or 5 point scale (0 to 4) ; 0=absent, 4=most severe. * Total score: 0 to 66.
Secondary Outcomes
- CGI-BP(baseline, 2week, 4week, 6week)
- HAM-A(baseline, 2week, 4week, 6week)
- YMRS(baseline, 2week, 4week, 6week)
- Q-LES-Q-SF(baseline, 2week, 4week, 6week)